GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (XPAR:ALMDP) » Definitions » Short-Term Debt

Medesis Pharma (XPAR:ALMDP) Short-Term Debt : €1.08 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medesis Pharma Short-Term Debt?

Medesis Pharma's Short-Term Debt for the quarter that ended in Jun. 2024 was €1.08 Mil.

Medesis Pharma's quarterly Short-Term Debt stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€1.08 Mil).


Medesis Pharma Short-Term Debt Historical Data

The historical data trend for Medesis Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma Short-Term Debt Chart

Medesis Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Medesis Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - 1.08

Medesis Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Medesis Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Medesis Pharma Business Description

Traded in Other Exchanges
N/A
Address
Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines